RATIONALE: Disturbed protein metabolism may result in malnutrition. A non-invasive low cost clinical tool to measure protein metabolism is lacking. Explorative research (n=1) with a newly developed non-invasive 13C-protein breath test suggested a decrease in protein oxidation after a protein restricted diet. Now, we aimed to test the effect of protein restriction in more subjects, to assess sensitivity of the test.METHODS: In this exploratory study, 14 healthy male subjects (23±3 y) participated. Habitual intake was assessed by a 4-day food diary. Next, subjects were instructed to use a 4-day isocaloric protein restricted diet (0.25 g protein/kg bw/day). After an overnight fast, a 30 g naturally enriched 13C-milk protein test drink was consumed, followed by collection of breath samples up to 330 min. Protein oxidation was analyzed by Isotope Ratio Mass Spectrometry. 24-h urine was collected on day 4 of the habitual diet, and on every day of the 4-day protein restricted diet, to assess actual change in protein intake.RESULTS: After the protein restricted diet, 30.2%±7.7 of the 30 g 13C-milk protein was oxidized over 330 min, compared to 30.6%±6.2 (NS) after the subject’s habitual diet (1.4±0.3 g protein/kg bw/day). Within subjects, both increase and decrease in oxidation was found. During the 4-day protein restricted diet, urinary urea:creatinine ratio decreased by 56%±10, consistent with a reduction in protein intake of 44%±15 (g/day) and 53%±12 (g/kg bw/day), based on urea and food diary, respectively.CONCLUSIONS: The breath test shows variation within subjects and between diets, which could be related to the sensitivity of the test. We cannot explain the variation by the measured variables. Alternatively, our results may implicate that in some of our subjects, protein intake did not sufficiently decrease to levels that could alter protein metabolism.
Low-grade inflammation and metabolic syndrome are seen in many chronic diseases, including rheumatoid arthritis (RA) and osteoarthritis (OA). Lifestyle interventions which combine different non-pharmacological therapies have shown synergizing effects in improving outcomes in patients with other chronic diseases or increased risk thereof, especially cardiovascular disease. For RA and metabolic syndrome-associated OA (MSOA), whole food plant-based diets (WFPDs) have shown promising results. A WFPD, however, had not yet been combined with other lifestyle interventions for RA and OA patients. In this protocol paper, we therefore present Plants for Joints, a multidisciplinary lifestyle program, based on a WFPD, exercise, and stress management. The objective is to study the effect of this program on disease activity in patients with RA (randomized controlled trial [RCT] 1), on a risk score for developing RA in patients with anti-citrullinated protein antibody (ACPA) positive arthralgia (RCT 2) and on pain, stiffness, and function in patients with MSOA (RCT 3), all in comparison with usual care.We designed three 16-week observer-blind RCTs with a waiting-list control group for patients with RA with low to moderate disease activity (2.6 ≤ Disease Activity Score [DAS28] ≤ 5.1, RCT 1, n = 80), for patients at risk for RA, defined by ACPA-positive arthralgia (RCT 2, n = 16) and for patients with metabolic syndrome and OA in the knee and/or hip (RCT 3, n = 80). After personal counseling on diet and exercise, participants join 10 group meetings with 6-12 other patients to receive theoretical and practical training on a WFPD, exercise, and stress management, while medication remains unchanged. The waiting-list control group receives usual care, while entering the program after the RCT. Primary outcomes are: difference in mean change between intervention and control groups within 16 weeks for the DAS28 in RA patients (RCT 1), the RA-risk score for ACPA positive arthralgia patients (RCT 2), and the Western Ontario and McMaster Universities Arthritis Index (WOMAC) score for MSOA patients (RCT 3). Continued adherence to the lifestyle program is measured in a two-year observational extension study.
Background and aims: Observational data indicate that diets rich in fruits and vegetables have a positive effect on inflammatory status, improve metabolic resilience and may protect against the development of non-communicable diseases. Nevertheless, experimental evidence demonstrating a causal relationship between nutrient intake (especially whole foods) and changes in metabolic health is scarce. This study investigated the pleiotropic effects of sulforaphane from broccoli sprouts, compared to pea sprouts, on biomarkers of endothelial function, inflammation and metabolic stress in healthy participants subjected to a standardized caloric challenge.Methods: In this double-blind, crossover, randomized, placebo-controlled trial 12 healthy participants were administered 16 g broccoli sprouts, or pea sprouts (placebo) followed by the standardized high-caloric drink PhenFlex given to disturb healthy homeostasis. Levels of inflammatory biomarkers and metabolic parameters were measured in plasma before and 2 h after the caloric overload.Results: Administration of broccoli sprouts promoted an increase in levels of CCL-2 induced by caloric load (p = 0.017). Other biomarkers (sICAM-1, sVCAM-1, hs-CRP, and IL-10) individually showed insignificant tendencies toward increase with administration of sulforaphane. Combining all studied biomarkers into the systemic low-grade inflammation score further confirmed upregulation of the inflammatory activity (p = 0.087) after sulforaphane. No significant effects on biomarkers of metabolic stress were detected.Conclusion: This study has demonstrated that sulforaphane facilitated development of a mild pro-inflammatory state during the caloric challenge, which could be suggestive of the onset of the hormetic response induced by this phytonutrient. The use of integrative outcomes measures such as the systemic low-grade inflammation score can be viewed as a more robust approach to study the subtle and pleiotropic effects of phytonutrients.Clinical trial registration:www.clinicaltrials.gov, identifier NCT05146804.Keywords: biomarkers; diet; glucoraphanin; hormesis; inflammation; nutrients; phenotypic flexibility; sulforaphane.
MULTIFILE
The European eel (Anguilla anguilla) is a delicacy fish and an integral part of the Dutch culinary history. However, the stock of adult eel has decreased significantly due to a precipitous recruitment of glass eel fall. This relates to multiple factors including obstacles in migration pathways, loss of habitat and chemical pollution. Consequently, Anguilla anguilla has become a critically endangered species and is protected under European legislation. One possible solution, explored on laboratory scale, is the captive reproduction of eels and growth of glass eel in aquaculture. A big challenge of this technique is the limiting aspect of possible nutrients for the eels in the larval stage, as the diet must be delivered in micrometric capsules (< 20 µm) with a high protein content. Such diets are not yet available on the market. Electrohydrodynamic atomization (EHDA) is a novel option to prepare a micro-diet suitable for eel larvae. EHDA is especially interesting for its narrow size distribution capabilities and for applications which require submicrometric sizes. This project aims to evaluate the use of EHDA to produce high protein content micrometric size capsules for feeding larval eels. If successful, this would assist in the captivity production of glass eel and to make the eel culture independent of wild catches, restoring the culinary market. The project will be conducted in two phases. Firstly, tests will be conducted to evaluate the necessary conditions of the capsules using EHDA. Subsequently, the obtained capsules will be tested as feed for eel larvae. The main objective is to favour the development of a more sustainable eel culture, regarding the possibilities of investigating the current fish in natura option and exchanging it for a captivity one.
The composition of diets and supplements given to bovine cattle are constantly evolving. These changes are driven by the social call for a more sustainable beef and dairy production, interests to influence the nutritional value of bovine products for human consumption, and to increase animal health. These adaptations can introduce (new) compounds in the beef and milk supply chain. Currently, the golden standard to study transfer of compounds from feed or veterinary medicine to cows and consequences for human health is performing animal studies, which are time consuming, costly and thus limited. Although animal studies are increasingly debated for ethical reasons, cows are still in the top 10 list of most used animals for animal experiments in Europe. There is, however, no widely applicable alternative modelling tool available to rapidly predict transfer of compounds, apart from individual components like cattle kinetic models and simple in vitro kinetic assays. Therefore, this project aims to develop a first-of-a-kind generic bovine kinetic modelling platform that predicts the transfer of compounds from medicine/supplements and feed to bovine tissues. This will provide new tools for the efficacy and safety evaluation of veterinary medicine and feed and facilitates a rapid evaluation of human health effects of bovine origin food products, thereby contributing to an increased safety in the cattle production chain and supporting product innovations, all without animal testing. This will be accomplished by integrating existing in silico and in vitro techniques into a generic bovine modelling platform and further developing state-of-the-art in vitro bovine organoid cell culturing systems. The platform can be used world-wide by stakeholders involved in the cattle industry (feed-/veterinary medicine industry, regulators, risk assessors). The project partners involve a strong combination of academia, knowledge institutes, small and medium enterprises, industry, branche-organisations and Proefdiervrij, all driven by their pursuit for animal free innovations.
